With prognostic indicators at hand, toss a coin. Half of all patients with cancer might be predicted to die as a result of the disease within 5 years. Ask yourself whether an individual patient might die within a year, and you are likely to be incorrect in your estimate. But what is certain is that you will not be able to cure everyone.
Palliative care offers patients and (note) their families a comprehensive package of care by a team of professionals who became experts in solving the difficult and multiple symptoms and problems that usually arise in advanced stages of the disease, helping to achieve comfort and eventually a peaceful death and bereavement. The practice has matured during the last 50 years, and it can be provided together with curative treatment. There are approximately 16,000 palliative care services worldwide, 1 and fast-growing research demonstrates the effectiveness of interventions, most notably that of homebased models of palliative care to support patients in their own homes, which is where most would prefer to be cared for and die, with family nearby.
2 In 2012, after publication of strong evidence from a phase III randomized controlled trial (RCT), 3 an American Society of Clinical Oncology provisional clinical opinion recommended consideration of combined standard oncology care and palliative care early in the course of illness for any patient with metastatic cancer and/or a high symptom burden. 4 In 2014, a landmark resolution was passed unanimously at the World Health Assembly that called for all state members to strengthen palliative care as a component of integrated treatment within the continuum of care. 5 The question of when to initiate is central to this hoped-for integration.
The articles by Bakitas et al 6 and Dionne-Odom et al 7 that accompany this editorial, reporting on the results of the ENABLE (Educate, Nurture, Advise Before Life Ends) III trial, evaluate outcomes for 207 patients and 122 family caregivers associated with the receipt of palliative care earlier rather than later in the course of illness. The authors used an innovative study design that was first attempted in palliative care by McWhinney et al 8 in the early 1990s in Canada. The fast-track trial, also known as a delayed-or deferred-intervention trial or a waiting list trial, randomly assigns patients to receive the intervention more quickly than they would normally (fast-track group) or after a period of waiting (control group). This design has the strength of an RCT but may be more acceptable to patients and clinicians because no one is denied access to the intervention. In addition, it allows an evaluation of the effect of waiting times. We have come a long way since McWhinney et al failed to complete their study because of inaccurate prognostication, unexpected deterioration, and early deaths, failure of patients to complete questionnaires because of weakness, exhaustion, or cognitive impairment, and dropout of caregivers as a result of their devastating and exhausting experience. At the 1-month follow-up, attrition rates were already 36% for patients and 49% for caregivers. During the last 10 years, Higginson et al 9 in the United Kingdom refined ways of handling these challenges and produced good quality palliative care trials using the methodology, recently showing that an integrated palliative and respiratory care service improved breathlessness mastery for patients with advanced disease and refractory breathlessness. 10 The ENABLE III trial investigators 6,7 used the method successfully for the first time to evaluate a model of home support in a rural setting in the United States. Surely, the study presents limitations, such as recruitment issues that led to a low response rate (38%) and failure to achieve the planned sample size (360 patients). This is a typical challenge in palliative care research and is common to most RCTs in the field. However, there are important strengths, such as the concealed allocation, follow-up of 75% of the sample at 3 months after enrollment, and robust outcome measurement by blinded data collectors. It is a rare, well-designed, and ethically appropriate palliative care trial.
The results are novel and mixed. The ENABLE III trial investigators 6,7 found statistically significant beneficial effects on survival and on family caregivers' depression. The survival finding is aligned with that found by Temel et al 3 for metastatic non-small-cell lung cancer, but it is the first time that a benefit for family caregivers has been shown; this suggests that receiving palliative care earlier in the course of illness is better not only for patients but also for their families. Unlike many chemotherapy treatments, there was no reported toxicity (negative effect) associated with the intervention. However, there were null results with respect to other outcomes (patients' quality of life, symptom impact, mood, place of death, family caregivers' quality of life and burden) and resource use. These are critical areas of the effectiveness of palliative care services. Whether this is a methodologic artifact (eg, a result of a lack of statistical power and multiple testing of a wide range of outcomes) or a true finding (eg, a result of interventional impact on some dimensions but not others) remains a question. The intervention consisted of an initial outpatient consultation by a board-certified palliative care physician followed by 6 weekly telephone coaching sessions (30 to 45 minutes each) by an advanced practice nurse (covering problem solving, symptom management, self-care, identification/coordination of local resources, communication, decision making, advance care planning, and life review), with monthly follow-up calls thereafter. The model is appropriate in its methods of outreach for patients living in remote rural areas. Increased staff input (from the physician and other professionals) and service intensity (eg, availability 24 hours per day, 7 days per week)
could help maximize the effect on symptoms and place of death. However, it should be noted that even with evidence of no effect on other outcomes, improved survival for patients and less depression for family members would be enough to justify the early introduction of palliative care. The effects found are relevant to practice for two reasons. First, the 15% increase in 1-year survival and 6% decrease in family caregivers' mean depression scores are clinically significant. For example, the survival effect was larger than the beneficial effect of chemotherapy compared with supportive care alone for advanced non-small-cell lung cancer (meta-analysis shows an absolute improvement in survival of 9% at 12 months).
11 On the other hand, interventions for family caregivers of patients with cancer are not usually successful in reducing caregivers' depression. A meta-analysis showed that among 16 studies that evaluated changes in caregivers' depression during the first 3 months after the intervention, the overall effect size was small and not significant. 12 The ENABLE III trial investigators 7 present us with an evidence-based solution that works for family caregivers. Second, it is worth noting that the control group received a form of so-called active comparator (delayed palliative care); hence, the effects could be greater when compared with an even later receipt of palliative care or no palliative care at all.
A reflection about timing is needed. Bakitas et al 6 and DionneOdom et al 7 identified participants within 30 to 60 days of their being informed of an advanced cancer diagnosis, cancer recurrence, or progression (consent was obtained a median of 28 days after notification of the diagnosis/recurrence/progression); after this, the intervention group received palliative care and the control participants received this care 3 months later. The findings are therefore reassuring to those who refer patients to palliative care within 2 months of telling them that their cancer is at an advanced stage. However, real-life studies show that palliative care tends to be routinely initiated later than for the study's control group and rarely within the time frame that was used for the intervention group. A 6-month chart review of 366 patients at the MD Anderson Cancer Center (2009 to 2010) showed that the time from advanced cancer diagnosis to palliative care consultation ranged from a median of 5 months for respiratory cancers to 16 months for breast and hematologic cancers. 13 In regions without integrated palliative care (81% of countries worldwide), 1 referrals could be further delayed. There are valid reasons why it may be difficult for oncologists to refer patients to palliative care earlier: prognostication inaccuracy (most of prognostication data are designed to be applied on populations, but individuals vary), the curative potential of anticancer therapies, problems predicting which trajectories will present complexities that oncologists cannot handle on their own and for which specialist palliative care is needed, the need to respect patient and family adaptation processes and coping mechanisms, and fears (of all involved parties) of engaging in sensitive end-of-life conversations. But half of all patients with cancer die as a result of the disease within 5 years, and we will not be able to cure them all.
Together with earlier findings on the benefits associated with the early integration of palliative care, the ENABLE III trial 6,7 urges a change of practice and culture. If palliative care makes a difference for patients and family caregivers, and if earlier is better, why wait?
